Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back
Leading European HTAs Call For Further Data Collection, Responsible Pricing
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
You may also be interested in...
New recommendations from UK academics, regulators and industry highlight the importance of proper planning when clinical studies are being prepared in areas such as oncology.
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.